BACKGROUND: @entity1822 represent the largest subtype of soft tissue @entity242 . Two subgroups can be distinguished, non-uterine (NULMS) and @entity1822 ( @entity1822 ). The aim of this retrospective study was to evaluate differences in clinical features and outcome between these two subgroups. METHODS: Outcome and clinical-pathological parameters between 50 @entity1 with NULMS and 45 @entity1 with @entity1822 were assessed, and compared between both groups. Univariate and multivariable survival analyses were performed. RESULTS: @entity1 with @entity1822 presented with larger @entity5 when compared to @entity1 with NULMS (p < 0.001). More @entity1 with @entity1822 initially presented with @entity3 (67% vs. 36%, p = 0.007). Most common metastatic site was lung for both subtypes (28% and 38%). Five-year overall survival (OS) rates of 82.6% and 41.2% and median OS times of 92.6 (range: 79.7-105.4) and 50.4 (range: 34.8-66.0) months were observed in @entity1 with NULMS and @entity1822 , respectively (p = 0.006). In multivariate analysis, initial @entity3 remained an independent prognostic factor in terms of OS (p < 0.0001). CONCLUSION: At time of diagnosis @entity1822 were larger and more often metastasized. Therefore @entity1 with @entity1822 showed unfavorable outcome when compared to NULMS. Later diagnosis might be caused by differences in symptoms and clinical presentation or a more aggressive biological @entity5 behavior.

Distinctive outcome in XXXX with non-uterine and uterine leiomyosarcoma.

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity242 :: ('MESH:D012509', 'Disease') :: ['sarcomas'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'tumors'] @entity1822 :: ('MESH:D007890', 'Disease') :: ['ULMS', 'Leiomyosarcomas', 'uterine leiomyosarcomas'] @entity3 :: ('MESH:D009362', 'Disease') :: ['metastatic disease']
@entity1 :: (9606,Species) :: ['patients']
